Terms ending in 2035
Every in-force patent on Pharmacyclics, Inc.'s record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,580,416 | Inhibitors of Bruton's Tyrosine Kinase In force · High confidence | Pharmacyclics LLC | In force | High confidence | |
| US 9,730,938 | Bruton's Tyrosine Kinase Inhibitor Combinations and Uses Thereof In force · High confidence | Pharmacyclics LLC | In force | High confidence | |
| US 10,898,461 | Novel Salts of 3-[(DIMETHYLAMINO)METHYL]-N-{2-[4-(HYDROXYCARBAMOYL) PHENOXY]ETHYLI-1-Benzofuran-2-Carboxamide, Related Crystalline Forms, Method for Preparing the Same and Pharmaceutical Compositions Containing the Same In force · Medium confidence | Pharmacyclics LLC | In force | Medium confidence | |
| US 10,226,466 | Methods of Treating Fibrosis In force · Medium confidence | Pharmacyclics LLC | In force | Medium confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.